Supplemental Approval For Benign Tumors May Double Afinitor's Market
Executive Summary
Novartis' Afinitor (everolimus) has approximately doubled its market size with FDA approval for a type of benign tumor that occurs in children with a genetic defect and was previously treatable only by surgery.
You may also be interested in...
CHMP Positive On Trajenta, Vectibix, Votubia And Eurartesim, But Negative On Bronchitol, Luveniq And Glybera
Europe's scientific advisory panel recommends Boehringer Ingelheim's Trajenta and Novartis's Votubia for approval, and clears new indications for Amgen's Vectibix.
CHMP Positive On Trajenta, Vectibix, Votubia And Eurartesim, But Negative On Bronchitol, Luveniq And Glybera
Europe's scientific advisory panel recommends Boehringer Ingelheim's Trajenta and Novartis's Votubia for approval, and clears new indications for Amgen's Vectibix.
Afinitor Wins FDA Nod For Kidney Cancer
The mTor inhibitor targets Sutent or Nexavar treatment failures.